Well being know-how startup Signos introduced a $20 million funding spherical on Wednesday, rising its foothold within the GLP-1-fueled weight reduction market and increasing its partnership with medical gadget large Dexcom.
GV, previously often known as Google Ventures, Dexcom and Blue Cross Blue Protect of Alabama invested on this newest spherical, which features a new distribution deal to place Signos’ subscription plans on Dexcom’s direct-to-consumer web site.
“Dexcom’s funding actually mirrored the shared perception in the way forward for glucose biosensing past diabetes administration,” Signos CEO Sharam Fouladgar-Mercer informed CNBC. “Their biosensor gives glucose knowledge. We translate that into precise steerage.”
Signos makes a synthetic intelligence-powered glucose monitoring system designed to assist with wholesome weight administration, the primary of its sort to be cleared by the Meals and Drug Administration. It was authorised in 2025.
It makes use of Dexcom’s off-the-shelf steady glucose monitor to measure how a consumer’s real-time way of life decisions can have an effect on their well being, like meal decisions, sleep and stress ranges. From there, the platform provides personalised suggestions to construct more healthy habits.
“No person desires to have a PhD in statistics to determine their very own physique, and so we’re actually serving to translate these glucose insights into precise suggestions, after which the sample recognition’s designed to help more healthy habits and sustainable weight administration,” Fouladgar-Mercer informed CNBC.
The startup declined to touch upon its valuation following the spherical.
The contemporary funding will go towards increasing its predictive AI options, like meal scoring, the place a consumer’s knowledge is used to warn them about whether or not a selected meals may spike their glucose ranges earlier than they eat it.
Fouladgar-Mercer stated the actual alternative with AI is translating biology into “sensible steerage folks can really use.”
“So you possibly can take a photograph of the meals and the AI will detect the entity and determine the macros and all of that, and likewise the actions, however actually it is how do you’re taking that and decide how your physique responds in actual time to offer you that suggestions to assist drive habits change,” he stated.
The service is supposed both for individuals who wish to complement their GLP-1 drug therapies or as a standalone weight administration system, Fouladgar-Mercer stated.
Signos’ new partnership with Dexcom may carry the startup better visibility within the booming weight reduction market, as demand for expensive GLP-1 medication like Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound continues to skyrocket.
Almost 74% of People are overweight or chubby, in accordance with authorities knowledge. Estimates from JP Morgan predict that roughly 25 million People shall be on a GLP-1 by 2030, greater than double the variety of sufferers in 2025.
Whereas Fouladgar-Mercer stated the corporate does not share metrics round income or buyer depend, he stated each income and consumer base grew tenfold over the previous six months. He added that “tens of hundreds” have participated in medical research.
“Simply monitoring outputs — like steps or coronary heart fee — are positive, but when we will not monitor the metabolic enter and the response, then we will not assist folks as successfully as we would like,” Fouladgar-Mercer stated.
